Options expected to have increasing volume: PFE BNTX CVX NBL
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall St tumbles on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil drops $1 as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Morgan Stanley Reiterates Equalweight Rating on Pfizer (PFE) Following COVID Vaccine Update
July 21, 2020 8:42 AM EDTMorgan Stanley analyst David Risinger reiterated an Equalweight rating and $36.00 price target on Pfizer (NYSE: PFE) following the company's COVID vaccine update. Results appear encouraging vs. MRNA and AZN, but x-trial comps are confounded.
Risinger await results from BNT162b2(full spike)... More
